Novel therapeutic modalities and drug delivery – erlotinib liposomes modified with galactosylated lipid: in vitro and in vivo investigations

Abstract

The aim of this study to develop galactosylated erlotinib liposomes for treatment of lung cancer. The liposomes were prepared by using solvent evaporation method. Various parameters such as particle size, zeta potential, entrapment efficiency, stability and in vitro drug release were determined. The size of liposomes (both conventional and modified) was 103.5 and 121.4 nm. The zeta potential and EE of both liposomes were -7.1 ± 1.3 mV, -1.2 ± 0.5 mV and (82.3 ± 1.9)%, (83.4 ± 1.5)%, respectively. It was found that modified liposomes increase the size of particles. The in vitro release results indicated that the release of erlotinib from galactosylated liposomes was similar to that of conventional liposome, demonstrating that the modification did not affect erlotinib release. From the result of in vivo, it proved that erlotinib liposomes can significantly improve the drug targeting, rapidly distribute the drug in the body, prolong the drug circulation time and significantly increase the relative bioavailability of the drug. Biodistribution studies showed that erlotinib from galactosylated liposomes had higher AUC inside liver than the injection group and no histological change occurred to the rat liver after the administration of erlotinib conventional and galactosylated liposomes.

Development of Liposomal Vesicles for Osimertinib Delivery to EGFR Mutation—Positive Lung Cancer Cells

“…The high cargo capacity and the existence of several clinically approved products make nanoparticulate liposomal vesicles ideal candidates for TKIs delivery [ 19 , 21 , 35 , 36 ]. The development of optimal liposome-based formulations requires evaluation of a range of parameters that determine performance in vivo, including size, charge, membrane fluidity, particle surface characteristics, and drug loading.…”

“…Several drug delivery strategies have been previously proposed to enhance the safety and efficacy of TKI-mediated therapy in lung cancer [ 16 , 17 , 18 , 19 , 20 , 21 ]. Liposomes are predominant nanocarriers among these delivery systems that have been developed for TKIs delivery.…”

Recent applications and strategies in nanotechnology for lung diseases

“…and significantly increase the relative bioavailability of the drug, and can be released quickly and continuously within the first 4 h after administration of the drug [213]. If it can be verified that the drugs related to AAK1 can inhibit SARS-CoV-2 from entering the target cells, and that nanotechnology is used to optimize the related drugs, it is expected that these will be used for the treatment of COVID-19.…”

The inhibition of miR-126 in cell migration and invasion of cervical cancer through regulating ZEB1

“…upregulation of miR-126 reduces cell proliferation and increases the apoptosis of colorectal cancer [19]. Besides, miR-126 also suppresses glioma cell proliferation, migration and invasion [20, 21]. In addition, miR-126 is downregulated in breast cancer and suppresses metastasis in breast cancer development [22].…”